Bank of New York Mellon Corp Increases Stake in Omeros Co. (NASDAQ:OMER)

Bank of New York Mellon Corp raised its holdings in shares of Omeros Co. (NASDAQ:OMER) by 16.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 218,580 shares of the biopharmaceutical company’s stock after buying an additional 31,081 shares during the quarter. Bank of New York Mellon Corp owned about 0.38% of Omeros worth $887,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Oppenheimer & Co. Inc. purchased a new stake in Omeros during the 1st quarter valued at about $85,000. Coldstream Capital Management Inc. grew its position in shares of Omeros by 42.1% in the fourth quarter. Coldstream Capital Management Inc. now owns 28,130 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 8,335 shares in the last quarter. Comerica Bank increased its holdings in shares of Omeros by 20.0% in the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 5,000 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Omeros by 75.5% during the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 12,951 shares in the last quarter. Finally, Cypress Capital Group lifted its position in Omeros by 40.0% during the second quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 10,000 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research note on Friday, August 16th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Tuesday, June 4th.

Omeros Stock Down 2.7 %

OMER stock opened at $3.92 on Friday. Omeros Co. has a 52-week low of $0.92 and a 52-week high of $5.68. The stock has a market cap of $227.16 million, a price-to-earnings ratio of -1.99 and a beta of 1.48. The business has a fifty day moving average of $4.36 and a two-hundred day moving average of $3.91.

Omeros (NASDAQ:OMER) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter. As a group, sell-side analysts anticipate that Omeros Co. will post -2.9 EPS for the current year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.